Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab

Ravi Murthy; Cathy Eng; Sunil Krishnan; David C. Madoff; Amit Habbu; Sara Canet; Marshall E. Hicks

doi:10.1016/j.jvir.2007.08.015

Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab

Ravi Murthy, Cathy Eng, Sunil Krishnan, David C. Madoff, Amit Habbu, Sara Canet, Marshall E. Hicks

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of ⁹⁰Y radioembolotherapy within the rapidly evolving landscape of systemic therapies for advanced unresectable colorectal cancer are limited. In that context, outcomes in patients who have received the recently approved biologic agents bevacizumab and cetuximab in addition to chemotherapy are unknown. This report briefly describes the authors' treatment experience with this cohort of patients.

Original language	English (US)
Pages (from-to)	1588-1591
Number of pages	4
Journal	Journal of Vascular and Interventional Radiology
Volume	18
Issue number	12
DOIs	https://doi.org/10.1016/j.jvir.2007.08.015
State	Published - Dec 2007

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jvir.2007.08.015

Cite this

@article{e427ebf916854b0180a8751c6281653a,

title = "Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab",

abstract = "Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of 90Y radioembolotherapy within the rapidly evolving landscape of systemic therapies for advanced unresectable colorectal cancer are limited. In that context, outcomes in patients who have received the recently approved biologic agents bevacizumab and cetuximab in addition to chemotherapy are unknown. This report briefly describes the authors' treatment experience with this cohort of patients.",

author = "Ravi Murthy and Cathy Eng and Sunil Krishnan and Madoff, {David C.} and Amit Habbu and Sara Canet and Hicks, {Marshall E.}",

year = "2007",

month = dec,

doi = "10.1016/j.jvir.2007.08.015",

language = "English (US)",

volume = "18",

pages = "1588--1591",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab

AU - Murthy, Ravi

AU - Eng, Cathy

AU - Krishnan, Sunil

AU - Madoff, David C.

AU - Habbu, Amit

AU - Canet, Sara

AU - Hicks, Marshall E.

PY - 2007/12

Y1 - 2007/12

N2 - Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of 90Y radioembolotherapy within the rapidly evolving landscape of systemic therapies for advanced unresectable colorectal cancer are limited. In that context, outcomes in patients who have received the recently approved biologic agents bevacizumab and cetuximab in addition to chemotherapy are unknown. This report briefly describes the authors' treatment experience with this cohort of patients.

AB - Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of 90Y radioembolotherapy within the rapidly evolving landscape of systemic therapies for advanced unresectable colorectal cancer are limited. In that context, outcomes in patients who have received the recently approved biologic agents bevacizumab and cetuximab in addition to chemotherapy are unknown. This report briefly describes the authors' treatment experience with this cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=36349008674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349008674&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2007.08.015

DO - 10.1016/j.jvir.2007.08.015

M3 - Article

C2 - 18057297

AN - SCOPUS:36349008674

SN - 1051-0443

VL - 18

SP - 1588

EP - 1591

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 12

ER -

Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this